Related Experiment Video
Updated: Sep 28, 2025
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
[Pay attention to the detection and evaluation of CD30 in pathological diagnosis of lymphoma]
1Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Abstract:
CD30 is a transmembrane glycoprotein of tumor necrosis factor receptor family, which is expressed differently in various lymphomas. It has specific effects on the proliferation and function of tumor cells. However, the significance of CD30 expression has not been fully recognized by clinicians and pathologists, and the detection and evaluation of CD30 have not been standardized. The role of CD30 in the diagnosis of lymphoma, detection methods and reporting standards are summarized in the paper to improve the understanding of CD30.
Insights
CD30, a key protein in lymphomas, impacts tumor cell growth. This paper clarifies its diagnostic role, detection methods, and reporting standards for better clinical understanding.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- CD30 is a transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily.
- Its expression varies across different lymphoma types, influencing tumor cell proliferation and function.
Purpose of the Study:
- To summarize the role of CD30 in lymphoma diagnosis.
- To review current CD30 detection methods and reporting standards.
- To enhance clinical and pathological understanding of CD30 expression in lymphomas.
Main Methods:
- Literature review and synthesis of existing data on CD30.
- Analysis of CD30 expression patterns in various lymphomas.
- Evaluation of diagnostic and prognostic significance of CD30.
Main Results:
- CD30 expression is heterogeneous in lymphomas and affects tumor cell behavior.
- Current methods for CD30 detection and evaluation lack standardization.
- Standardization is crucial for accurate diagnosis and treatment decisions.
Conclusions:
- Improved understanding and standardized evaluation of CD30 are essential for lymphoma diagnosis and management.
- Further research is needed to refine detection and reporting protocols.
- CD30 remains a significant biomarker in hematologic malignancies.
More Related Videos
07:52Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016